A Phase 2b, Multi-center, Randomized, Double Blind, Placebo-controlled, Crossover Study to Evaluate Multiple Doses of ALLN-177 in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2017
At a glance
- Drugs ALLN 177 (Primary)
- Indications Hyperoxaluria
- Focus Therapeutic Use
- Sponsors Allena Pharmaceuticals
- 17 Jan 2017 Status changed from active, no longer recruiting to completed.
- 17 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Jan 2017.
- 17 Jun 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Nov 2016.